Histogen Dividendos y recompras

Dividendo controles de criterios 0/6

Histogen no tiene historial de pago de dividendo.

Información clave

n/a

Rentabilidad por dividendo

8.4%

Rendimiento de la recompra

Rendimiento total para el accionista	8.4%
Rendimiento futuro de los dividendos	n/a
Crecimiento de los dividendos	n/a
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Ratio de pago	n/a

Últimas actualizaciones de dividendos y recompras

No hay actualizaciones

Recent updates

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de HSTO.Q han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de HSTO.Q han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Histogen vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de HSTO.Q con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (HSTO.Q)	n/a
Suelo de mercado 25% (US)	1.4%
Techo de mercado 25% (US)	4.3%
Media de la industria (Biotechs)	2.3%
Analista de previsiones (HSTO.Q) (hasta 3 años)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de HSTO.Q en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de HSTO.Q en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: No hay datos suficientes para calcular el ratio de pago de HSTO.Q para determinar si sus pagos de dividendos están cubiertos por los beneficios.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que HSTO.Q no ha comunicado ningún pago.

Histogen Dividendos y recompras

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos y recompras

Recent updates

Histogen Inc. Filed for Bankruptcy

Histogen Inc. Files Form 15

Histogen Inc.(OTCPK:HSTO) dropped from NASDAQ Composite Index

Nasdaq To File A Form 25-NSE with the SEC, To Remove Histogen's Securities from Listing and Registration

Histogen Inc.(NasdaqCM:HSTO) dropped from S&P TMI Index

Histogen Inc. Announces Executive Changes

Histogen Intends to File Certificate of Dissolution, Delist its Shares of Common Stock from The Nasdaq Capital Market

Histogen Receives Letter from the Listing Qualifications Department of the Nasdaq Regarding Listing Rule 5550(a)(2)

Histogen Inc. Hires Alfred P. Spada as Chief Scientific Officer

Histogen stock down 8% after Q2 loss, on track for six-day losing streak

Histogen Inc. to Report Q2, 2022 Results on Aug 11, 2022

Histogen Inc. announced that it expects to receive $5 million in funding

Histogen announces pricing of $5M private placement

Histogen Announces 1-for-20 Reverse Stock Split

First quarter 2022 earnings released: US$0.013 loss per share (vs US$0.14 loss in 1Q 2021)

Price target decreased to US$2.25

Histogen Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Histogen Inc. to Report Q4, 2021 Results on Mar 10, 2022

Histogen Not Regained Compliance with the Minimum Bid Price Requirement

Histogen Inc. announced that it has received $3.500001 million in funding

Histogen Inc. announced that it expects to receive $3.500001 million in funding

We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate

Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration

Histogen Inc. and its partner Amerimmune LLC Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients

Histogen jumps 11% after Intracoastal Capital reports 5.6% stake

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $6.57503 million.

Histogen enters $6.5M at-the-market direct offering

Histogen Provides Update on its Development Programs and Pipeline Focus

Histogen and Amerimmune Reports Publication on Emricasan in COVID-19

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.55 loss in 1Q 2020)

Histogen Provides Business Update

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic Covid-19 Patients

Histogen Announces Removal of Clinical Hold by FDA for HST-003 IND to Initiate a Phase 1/2 Trial for Knee Cartilage Regeneration

Full year 2020 earnings released: US$2.08 loss per share (vs US$0.89 loss in FY 2019)

Histogen Inc. Announces Board Changes

Independent Director has left the company

Histogen Inc. to Report Q4, 2020 Results on Mar 11, 2021

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day high: US$1.72

Histogen Inc. Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $14 million.

Histogen under pressure on pricing $14M upsized public offering

Histogen Inc. Announces Filing an Investigational New Drug Application for HST-003

New 90-day low: US$1.19

Histogen files IND application for regenerative human matrix

Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

New 90-day low: US$1.31

Histogen soars after HST-001 data in male pattern baldness

Histogen Inc. has completed a Follow-on Equity Offering in the amount of $4.500016 million.

Histogen Inc. to Report Q3, 2020 Results on Nov 12, 2020

Histogen Inc. and Amerimmune Llc Enters into A Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of Covid-19

Histogen Inc. Appoints Moya Daniels as Executive Vice President and Head of Regulatory, Quality and Clinical Operations

Histogen Announces Completion of Final Dosing Timepoint Milestone in its 1b/2a Trial for Androgenic Alopecia in Men

Histogen Announces Update for its HST-002 Dermal Filler Program

Histogen Inc. Announces Phase 1/2 Clinical Trial Designed to Evaluate HST-003

New 90-day low - US$1.64

First half earnings released

Histogen Inc. to Report Q2, 2020 Results on Aug 13, 2020

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos